The University of Chicago Header Logo

Gini Fleming

Concepts (645)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
35
2022
243
6.390
Why?
Antineoplastic Combined Chemotherapy Protocols
90
2023
2666
6.170
Why?
Ovarian Neoplasms
55
2023
829
5.370
Why?
Breast Neoplasms
67
2023
3303
3.750
Why?
Paclitaxel
42
2023
484
2.450
Why?
Tamoxifen
19
2022
177
2.270
Why?
Neoplasms, Glandular and Epithelial
10
2017
81
2.230
Why?
Neoplasm Recurrence, Local
41
2023
1538
2.190
Why?
Antineoplastic Agents
34
2023
2386
2.180
Why?
Chemotherapy, Adjuvant
34
2023
527
1.910
Why?
Genital Neoplasms, Female
8
2023
118
1.800
Why?
Uterine Cervical Neoplasms
9
2023
326
1.760
Why?
Female
201
2023
51997
1.590
Why?
Sirolimus
9
2018
181
1.570
Why?
Androstadienes
12
2022
71
1.350
Why?
Antineoplastic Agents, Hormonal
17
2022
161
1.310
Why?
Aromatase Inhibitors
9
2018
29
1.280
Why?
Receptors, Glucocorticoid
7
2022
145
1.190
Why?
Humans
214
2023
98799
1.160
Why?
Ovary
9
2019
262
1.160
Why?
Fallopian Tube Neoplasms
8
2019
39
1.140
Why?
Aged
119
2023
21986
1.110
Why?
Peritoneal Neoplasms
9
2019
196
1.070
Why?
Middle Aged
130
2023
29642
1.050
Why?
Fluorouracil
9
2015
543
1.050
Why?
Carcinoma
7
2014
442
1.050
Why?
Disease-Free Survival
35
2022
1196
1.010
Why?
Aged, 80 and over
57
2023
7461
0.960
Why?
Carboplatin
17
2023
331
0.950
Why?
Adult
116
2023
29698
0.930
Why?
Radiotherapy, Adjuvant
8
2019
325
0.900
Why?
Premenopause
16
2022
65
0.900
Why?
Benzimidazoles
8
2022
120
0.890
Why?
Neoplasm Metastasis
18
2020
1102
0.840
Why?
Drug Administration Schedule
25
2021
837
0.810
Why?
Antibodies, Monoclonal
14
2022
1422
0.800
Why?
Neoplasms
26
2021
3382
0.800
Why?
Cisplatin
17
2023
578
0.800
Why?
Antimetabolites, Antineoplastic
7
2021
246
0.790
Why?
Drug Resistance, Neoplasm
10
2020
671
0.780
Why?
Uterine Neoplasms
4
2010
289
0.780
Why?
Carcinosarcoma
5
2020
31
0.750
Why?
Receptors, Estrogen
10
2019
431
0.740
Why?
Quality of Life
16
2020
1904
0.730
Why?
Antibodies, Monoclonal, Humanized
20
2022
1105
0.730
Why?
Antineoplastic Agents, Phytogenic
16
2008
272
0.720
Why?
Combined Modality Therapy
15
2023
1754
0.710
Why?
Prognosis
24
2023
4139
0.700
Why?
Clinical Trials as Topic
14
2020
1128
0.680
Why?
Poly(ADP-ribose) Polymerase Inhibitors
6
2021
90
0.670
Why?
Pyridines
6
2023
317
0.650
Why?
Neoplasm Staging
26
2021
2087
0.640
Why?
Cystadenocarcinoma, Serous
7
2019
69
0.620
Why?
Megestrol Acetate
3
2016
9
0.600
Why?
Quinazolines
8
2019
222
0.600
Why?
Peripheral Nervous System Diseases
2
2015
94
0.580
Why?
Leucovorin
5
2015
205
0.570
Why?
Hormone Replacement Therapy
1
2020
105
0.560
Why?
Treatment Outcome
36
2021
9806
0.560
Why?
Doxorubicin
14
2019
285
0.550
Why?
Circadian Rhythm
2
2015
295
0.520
Why?
Receptors, Progesterone
7
2019
208
0.520
Why?
Gene Regulatory Networks
1
2020
342
0.500
Why?
Geriatric Assessment
1
2018
193
0.490
Why?
Dose-Response Relationship, Drug
19
2020
1949
0.480
Why?
Bevacizumab
11
2022
255
0.450
Why?
Age Factors
5
2023
1976
0.420
Why?
Mutation
8
2023
4443
0.420
Why?
Filgrastim
5
2020
56
0.410
Why?
Topotecan
7
2019
47
0.410
Why?
Vinblastine
3
2004
84
0.410
Why?
Infusions, Intravenous
10
2019
403
0.400
Why?
Mastectomy
9
2020
277
0.400
Why?
Biomarkers, Tumor
9
2020
1786
0.400
Why?
Randomized Controlled Trials as Topic
14
2019
995
0.390
Why?
Deoxycytidine
6
2021
218
0.380
Why?
Survival Rate
14
2020
2057
0.370
Why?
Sarcoma
3
2007
222
0.370
Why?
Granulocyte Colony-Stimulating Factor
8
2004
158
0.360
Why?
Survival Analysis
14
2021
1530
0.360
Why?
Immunohistochemistry
10
2022
1818
0.350
Why?
Molecular Targeted Therapy
4
2020
331
0.350
Why?
Hereditary Breast and Ovarian Cancer Syndrome
2
2021
12
0.350
Why?
Radiosurgery
3
2021
352
0.350
Why?
Leiomyosarcoma
2
2011
48
0.350
Why?
Young Adult
20
2023
7598
0.340
Why?
Anilides
2
2022
50
0.320
Why?
Pyrazoles
4
2023
162
0.320
Why?
Benzenesulfonates
2
2011
49
0.320
Why?
Medical Oncology
4
2016
426
0.320
Why?
Indoles
8
2019
340
0.320
Why?
B7-H1 Antigen
3
2022
333
0.320
Why?
Triptorelin Pamoate
5
2019
8
0.320
Why?
Phthalazines
4
2022
60
0.310
Why?
Protein Kinase Inhibitors
2
2012
642
0.300
Why?
Survivors
2
2008
211
0.290
Why?
Ki-67 Antigen
2
2022
70
0.290
Why?
Lymphedema
2
2020
92
0.290
Why?
Pyrroles
4
2020
166
0.290
Why?
Angiogenesis Inhibitors
5
2015
281
0.290
Why?
Taxoids
5
2022
127
0.290
Why?
Follow-Up Studies
16
2022
4049
0.280
Why?
Women's Health
2
2007
120
0.280
Why?
Administration, Oral
12
2019
677
0.280
Why?
Adenocarcinoma, Clear Cell
4
2017
64
0.270
Why?
Self Report
4
2020
357
0.270
Why?
Nervous System Diseases
2
2007
169
0.270
Why?
Enzyme Inhibitors
5
2021
641
0.270
Why?
Chemoradiotherapy
2
2020
337
0.260
Why?
Maximum Tolerated Dose
6
2018
265
0.260
Why?
Antibiotics, Antineoplastic
4
2012
111
0.260
Why?
Etoposide
4
2007
207
0.250
Why?
Platinum
1
2007
68
0.250
Why?
Piperidines
2
2019
177
0.250
Why?
Complementary Therapies
1
2007
58
0.240
Why?
Kidney Diseases
3
2003
313
0.240
Why?
Piperazines
3
2019
308
0.240
Why?
Neutropenia
9
2018
211
0.230
Why?
Leukocytes, Mononuclear
4
2022
213
0.230
Why?
Proportional Hazards Models
8
2021
925
0.230
Why?
Ribose
2
2022
21
0.230
Why?
TOR Serine-Threonine Kinases
4
2018
224
0.230
Why?
Metformin
2
2018
134
0.230
Why?
Kaplan-Meier Estimate
10
2019
909
0.220
Why?
Albumins
4
2023
126
0.220
Why?
Cyclophosphamide
5
2015
285
0.220
Why?
Cyclohexanecarboxylic Acids
2
2015
17
0.220
Why?
Platinum Compounds
3
2019
29
0.210
Why?
Liver Diseases
2
2003
250
0.210
Why?
Neoplasm Grading
4
2021
425
0.210
Why?
Neoadjuvant Therapy
4
2023
477
0.200
Why?
Rosaniline Dyes
1
2023
9
0.200
Why?
Pelvic Neoplasms
1
2004
43
0.200
Why?
Injections, Intraperitoneal
1
2003
102
0.200
Why?
Male
38
2021
47475
0.200
Why?
Niacinamide
3
2014
105
0.200
Why?
Adenocarcinoma
4
2015
1215
0.190
Why?
Suprachiasmatic Nucleus
1
2003
5
0.190
Why?
DNA Mismatch Repair
2
2022
60
0.190
Why?
Phenylurea Compounds
3
2014
112
0.190
Why?
Prospective Studies
7
2020
4837
0.190
Why?
Recombinant Proteins
7
2004
994
0.180
Why?
Lymphatic Metastasis
6
2016
519
0.180
Why?
Disease Progression
5
2019
1621
0.180
Why?
Cohort Studies
7
2023
3242
0.180
Why?
Estrogens
2
2016
202
0.180
Why?
Recombinational DNA Repair
1
2021
11
0.180
Why?
Epigenesis, Genetic
3
2023
595
0.180
Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2021
17
0.170
Why?
Capecitabine
2
2020
103
0.170
Why?
Safety
3
2020
138
0.170
Why?
Genes, BRCA2
5
2021
162
0.170
Why?
Aminopyridines
1
2022
54
0.170
Why?
Antineoplastic Agents, Immunological
3
2020
238
0.170
Why?
Genes, BRCA1
5
2021
191
0.170
Why?
Oxidoreductases
3
2003
112
0.170
Why?
Triazoles
3
2009
118
0.170
Why?
Azacitidine
2
2019
152
0.160
Why?
Pyrimidinones
1
2021
51
0.160
Why?
Polyethylene Glycols
3
2019
383
0.160
Why?
Time Factors
11
2019
5586
0.160
Why?
Vaccines, DNA
1
2020
19
0.160
Why?
Benzodiazepines
1
2020
56
0.150
Why?
Human papillomavirus 18
1
2020
22
0.150
Why?
Phosphatidylinositol 3-Kinases
2
2023
286
0.150
Why?
Clinical Trials, Phase III as Topic
4
2019
172
0.150
Why?
Human papillomavirus 16
1
2020
46
0.150
Why?
Maintenance Chemotherapy
4
2021
96
0.150
Why?
Trastuzumab
4
2009
98
0.150
Why?
Body Weight
1
2021
457
0.150
Why?
Sexual Dysfunction, Physiological
1
2020
77
0.150
Why?
Receptors, Vascular Endothelial Growth Factor
3
2014
58
0.150
Why?
Immunoglobulins, Intravenous
1
2019
67
0.140
Why?
Double-Blind Method
7
2021
1793
0.140
Why?
Gene Expression Regulation, Neoplastic
4
2019
1400
0.140
Why?
Immunoconjugates
1
2020
140
0.140
Why?
Surveys and Questionnaires
2
2007
3058
0.140
Why?
Radiation Oncology
3
2016
130
0.140
Why?
Myasthenia Gravis
1
2019
85
0.140
Why?
Depressive Disorder
1
2020
232
0.140
Why?
Indazoles
1
2019
65
0.140
Why?
Vaginal Neoplasms
1
1999
86
0.140
Why?
Ketoconazole
3
2012
23
0.140
Why?
Carcinoma, Endometrioid
2
2017
60
0.140
Why?
Steroids
1
2019
168
0.140
Why?
Sleep Wake Disorders
1
2020
139
0.140
Why?
Recurrence
4
2018
1274
0.140
Why?
Febrile Neutropenia
1
2018
16
0.140
Why?
Thrombocytopenia
5
2018
194
0.130
Why?
Ipilimumab
1
2018
69
0.130
Why?
Retreatment
1
2018
106
0.130
Why?
Drug-Related Side Effects and Adverse Reactions
1
2020
220
0.130
Why?
Stathmin
1
2017
3
0.130
Why?
Mifepristone
2
2015
59
0.130
Why?
Vascular Endothelial Growth Factor Receptor-2
2
2015
82
0.130
Why?
United States
10
2021
8387
0.130
Why?
Camptothecin
4
2003
198
0.130
Why?
California
5
2020
182
0.130
Why?
Body Mass Index
4
2021
869
0.120
Why?
T-Lymphocytes, Cytotoxic
1
2018
322
0.120
Why?
Postoperative Care
1
2018
239
0.120
Why?
Disease Management
1
2019
378
0.120
Why?
Health Services Misuse
1
2016
20
0.120
Why?
Incidence
4
2020
1798
0.120
Why?
Drug Monitoring
1
2018
167
0.120
Why?
Antineoplastic Agents, Alkylating
1
1997
136
0.120
Why?
Research Design
3
2021
652
0.120
Why?
Estradiol
3
2016
268
0.120
Why?
Germ-Line Mutation
4
2021
404
0.120
Why?
Benzamides
1
2017
260
0.120
Why?
Nitriles
2
2009
172
0.120
Why?
Neovascularization, Pathologic
2
2015
356
0.120
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
1996
114
0.120
Why?
Antigens, Neoplasm
1
2018
366
0.120
Why?
Fatigue
4
2019
187
0.120
Why?
Class I Phosphatidylinositol 3-Kinases
1
2016
84
0.110
Why?
Pancreatic Neoplasms
1
2022
782
0.110
Why?
Chromatin
1
2019
465
0.110
Why?
Adjuvants, Immunologic
3
2022
177
0.110
Why?
Leukemia, Myeloid
1
1997
241
0.110
Why?
Induction Chemotherapy
3
2021
152
0.110
Why?
Preoperative Care
1
2018
420
0.110
Why?
Amines
1
2015
31
0.110
Why?
Receptors, Antigen, T-Cell
1
2018
454
0.110
Why?
Response Evaluation Criteria in Solid Tumors
3
2021
61
0.110
Why?
Nanomedicine
1
2015
19
0.110
Why?
Ascites
1
2015
55
0.110
Why?
Collagen Type I
1
2015
75
0.110
Why?
PTEN Phosphohydrolase
1
2016
154
0.110
Why?
Multicenter Studies as Topic
2
2013
195
0.110
Why?
Insulin-Like Growth Factor I
2
2013
118
0.110
Why?
Area Under Curve
7
2018
341
0.110
Why?
gamma-Aminobutyric Acid
1
2015
85
0.110
Why?
Transcriptome
2
2018
828
0.110
Why?
Antifungal Agents
2
2007
127
0.110
Why?
Neural Stem Cells
1
2015
73
0.110
Why?
Precision Medicine
1
2020
512
0.110
Why?
Predictive Value of Tests
5
2015
1792
0.110
Why?
Uracil
3
2005
58
0.110
Why?
Benzazepines
1
2015
64
0.110
Why?
Urinary Bladder Neoplasms
1
1999
403
0.100
Why?
Body Fluids
1
2014
35
0.100
Why?
Proto-Oncogene Proteins c-akt
1
2016
369
0.100
Why?
Lymph Node Excision
3
2020
238
0.100
Why?
Cervix Uteri
1
2014
73
0.100
Why?
Estrogen Receptor alpha
1
2015
159
0.100
Why?
Obstetric Labor, Premature
1
2014
58
0.100
Why?
Ketones
1
2013
15
0.100
Why?
Furans
1
2013
19
0.100
Why?
Meningeal Carcinomatosis
1
2013
8
0.100
Why?
Rectal Neoplasms
1
2015
139
0.100
Why?
Tumor Suppressor Proteins
1
2016
318
0.100
Why?
Fibronectins
1
2014
104
0.100
Why?
Cytotoxicity, Immunologic
2
2018
218
0.100
Why?
Drug Discovery
1
2015
124
0.100
Why?
Survival
2
2021
22
0.100
Why?
Research
1
2015
258
0.100
Why?
Glucocorticoids
2
2022
371
0.100
Why?
In Situ Hybridization, Fluorescence
3
2022
369
0.100
Why?
Tubulin Modulators
1
2013
23
0.100
Why?
Insulin-Like Growth Factor Binding Protein 3
1
2013
21
0.100
Why?
Insulin-Like Growth Factor II
1
2013
32
0.100
Why?
Lung Neoplasms
4
2018
2474
0.100
Why?
Receptor, IGF Type 1
1
2013
45
0.100
Why?
Vomiting
3
1999
109
0.100
Why?
Chordoma
1
1993
45
0.090
Why?
Folic Acid Antagonists
1
1992
17
0.090
Why?
Pyrimidines
2
2012
416
0.090
Why?
Isoquinolines
2
2023
58
0.090
Why?
Vagina
1
2014
188
0.090
Why?
Sacrum
1
1993
82
0.090
Why?
Salvage Therapy
2
2008
241
0.090
Why?
Neoplasms, Hormone-Dependent
2
2003
35
0.090
Why?
Risk Factors
7
2019
6295
0.090
Why?
Hypoglycemic Agents
1
2016
416
0.090
Why?
Intensive Care Units
1
2016
476
0.090
Why?
Gastrointestinal Diseases
1
2014
156
0.090
Why?
CA-125 Antigen
2
2022
24
0.090
Why?
Models, Neurological
1
2015
416
0.090
Why?
Megestrol
1
1992
4
0.090
Why?
Dihydrouracil Dehydrogenase (NADP)
3
2003
28
0.090
Why?
Gene Amplification
2
2009
142
0.090
Why?
Interferon-alpha
3
1997
191
0.090
Why?
Peptides
1
2015
671
0.090
Why?
Dexamethasone
2
2014
318
0.090
Why?
Xenograft Model Antitumor Assays
3
2019
559
0.090
Why?
Polymorphism, Genetic
2
2008
832
0.090
Why?
Brachytherapy
2
2004
139
0.090
Why?
Radiotherapy, Conformal
2
2002
88
0.080
Why?
Anemia
3
2018
135
0.080
Why?
Metoclopramide
1
1991
12
0.080
Why?
Radiotherapy Dosage
3
2018
478
0.080
Why?
Antiemetics
1
1991
28
0.080
Why?
Obesity
1
2018
1079
0.080
Why?
Sulfonamides
1
2013
352
0.080
Why?
Genes, erbB-2
2
2007
25
0.080
Why?
Early Medical Intervention
2
2020
21
0.080
Why?
Hospitalization
1
2016
993
0.080
Why?
Lymph Nodes
3
2017
563
0.080
Why?
Pilot Projects
3
2022
978
0.080
Why?
Exercise Therapy
2
2020
98
0.080
Why?
Recombinant Fusion Proteins
1
2011
557
0.080
Why?
Cytoreduction Surgical Procedures
2
2021
105
0.080
Why?
Blood Pressure
1
2014
923
0.080
Why?
Canada
2
2021
210
0.070
Why?
Membrane Glycoproteins
1
1992
446
0.070
Why?
Practice Guidelines as Topic
1
2016
1116
0.070
Why?
Dual Specificity Phosphatase 1
1
2009
17
0.070
Why?
Diarrhea
3
2019
180
0.070
Why?
Postoperative Complications
1
2020
2719
0.070
Why?
Hysterectomy
3
2019
175
0.070
Why?
Feasibility Studies
4
2013
818
0.070
Why?
Prostatic Neoplasms
2
2018
1846
0.070
Why?
Immunotherapy
1
2015
831
0.070
Why?
Diabetes Mellitus
1
1996
815
0.070
Why?
Risk Assessment
4
2019
2604
0.070
Why?
Carcinoma, Lobular
1
2009
84
0.070
Why?
Sentinel Lymph Node Biopsy
2
2020
88
0.070
Why?
Reproducibility of Results
2
2021
2799
0.070
Why?
Drug Interactions
4
2011
240
0.070
Why?
Immediate-Early Proteins
1
2009
160
0.070
Why?
Socioeconomic Factors
2
2008
675
0.070
Why?
BRCA2 Protein
2
2019
178
0.070
Why?
Decision Making
2
2016
691
0.070
Why?
Carcinoma, Ductal, Breast
1
2009
167
0.070
Why?
Gene Expression Profiling
3
2020
1572
0.070
Why?
Aging
2
2003
772
0.070
Why?
Anxiety
2
2008
376
0.070
Why?
Chicago
4
2015
1520
0.060
Why?
BRCA1 Protein
2
2019
222
0.060
Why?
Nausea
3
2018
95
0.060
Why?
Tegafur
2
2005
17
0.060
Why?
Bilirubin
2
2007
135
0.060
Why?
Drug Delivery Systems
1
2009
202
0.060
Why?
Dose-Response Relationship, Radiation
2
2018
193
0.060
Why?
Cell Line, Tumor
3
2019
2913
0.060
Why?
Glucuronosyltransferase
2
2013
178
0.060
Why?
Drug Synergism
2
2018
317
0.060
Why?
Neurons
1
2015
1634
0.060
Why?
Patient Satisfaction
2
2008
519
0.060
Why?
Animals
8
2019
29045
0.060
Why?
Ovariectomy
2
2019
98
0.060
Why?
Interleukin-2
2
2008
246
0.060
Why?
Polymorphism, Single Nucleotide
2
2020
2577
0.060
Why?
Surgical Oncology
2
2016
34
0.060
Why?
Disease Models, Animal
3
2019
2581
0.060
Why?
DNA-Binding Proteins
2
2023
1275
0.060
Why?
Ribosomal Protein S6 Kinases, 70-kDa
2
2018
46
0.060
Why?
Stroke
1
2015
1163
0.060
Why?
Treatment Failure
3
2008
300
0.060
Why?
Patient Selection
3
2008
725
0.060
Why?
Killer Cells, Natural
2
2008
298
0.060
Why?
Creatinine
2
2003
315
0.060
Why?
Abdomen
1
2005
121
0.060
Why?
Enzyme-Linked Immunosorbent Assay
3
2014
374
0.050
Why?
Psychometrics
1
2007
359
0.050
Why?
ErbB Receptors
1
2008
517
0.050
Why?
Interleukin-6
1
2006
283
0.050
Why?
Ontario
2
2015
32
0.050
Why?
Comorbidity
3
2021
1037
0.050
Why?
Logistic Models
4
2014
1276
0.050
Why?
Retrospective Studies
6
2018
11104
0.050
Why?
Infusions, Parenteral
2
2019
47
0.050
Why?
Pharmacogenetics
1
2008
474
0.050
Why?
Data Interpretation, Statistical
2
2021
312
0.050
Why?
Stress, Psychological
1
2007
384
0.050
Why?
Genetic Counseling
1
2023
111
0.050
Why?
CD56 Antigen
1
2002
18
0.050
Why?
Chromium
1
2002
17
0.050
Why?
Regression Analysis
2
2008
578
0.050
Why?
Diphosphates
1
2022
15
0.050
Why?
Pentostatin
1
2002
13
0.050
Why?
Bridged-Ring Compounds
1
2022
16
0.050
Why?
Immunoenzyme Techniques
1
2002
291
0.050
Why?
Adenosine Diphosphate
1
2022
61
0.050
Why?
Societies, Medical
2
2016
687
0.050
Why?
Depression
1
2007
625
0.040
Why?
Food-Drug Interactions
1
2002
19
0.040
Why?
Allelic Imbalance
1
2021
22
0.040
Why?
Case-Control Studies
3
2021
2017
0.040
Why?
Loss of Heterozygosity
1
2021
85
0.040
Why?
Counseling
1
2023
191
0.040
Why?
Neoplasm, Residual
1
2023
205
0.040
Why?
Epigenomics
1
2022
112
0.040
Why?
Neoplasm Proteins
2
2019
553
0.040
Why?
Oligodeoxyribonucleotides, Antisense
1
2001
15
0.040
Why?
Genomic Instability
1
2021
92
0.040
Why?
Proto-Oncogene Proteins c-raf
1
2001
51
0.040
Why?
Thionucleotides
1
2001
54
0.040
Why?
Body Weights and Measures
1
2021
25
0.040
Why?
Ifosfamide
1
2001
37
0.040
Why?
Hematopoietic Stem Cell Mobilization
1
2001
52
0.040
Why?
Radiotherapy
2
2003
325
0.040
Why?
Ligands
1
2022
492
0.040
Why?
Peripheral Nerves
1
2001
40
0.040
Why?
Adolescent
4
2019
10168
0.040
Why?
Patient Participation
1
2003
251
0.040
Why?
Flow Cytometry
1
2002
722
0.040
Why?
Head and Neck Neoplasms
1
2008
1091
0.040
Why?
Patient Compliance
1
2002
247
0.040
Why?
Breast
1
2023
317
0.040
Why?
Methotrexate
1
2001
229
0.040
Why?
Tumor Suppressor Protein p53
1
2004
470
0.040
Why?
Dipeptidases
1
2020
1
0.040
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.040
Why?
Axilla
2
2016
109
0.040
Why?
International Agencies
1
2020
35
0.040
Why?
Remission Induction
2
2006
764
0.040
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
28
0.040
Why?
Thalidomide
1
2000
57
0.040
Why?
Papillomavirus E7 Proteins
1
2020
31
0.040
Why?
Oncogene Proteins, Viral
1
2020
34
0.040
Why?
Arm
1
2020
99
0.040
Why?
Chronic Disease
1
2023
991
0.040
Why?
Vascular Endothelial Growth Factor A
3
2008
402
0.040
Why?
Range of Motion, Articular
1
2020
179
0.040
Why?
Leukopenia
2
1997
66
0.040
Why?
Hand
1
2020
143
0.040
Why?
Biomarkers
3
2014
2026
0.040
Why?
Capsules
2
2013
39
0.040
Why?
Intention to Treat Analysis
1
2019
82
0.040
Why?
Sentinel Lymph Node
1
2019
23
0.040
Why?
Kidney Neoplasms
2
2018
556
0.040
Why?
Genetic Testing
1
2023
610
0.040
Why?
Proto-Oncogene Proteins c-bcl-2
1
2000
213
0.040
Why?
Bone Marrow
1
2001
419
0.040
Why?
Mice
3
2019
12762
0.040
Why?
Genotype
2
2020
1895
0.040
Why?
Tumor Cells, Cultured
2
2009
1029
0.040
Why?
Hydroxyurea
1
1999
233
0.030
Why?
Chemistry, Pharmaceutical
2
2004
79
0.030
Why?
Drug Evaluation
2
2001
109
0.030
Why?
Global Health
1
2020
216
0.030
Why?
Breast Neoplasms, Male
1
2018
34
0.030
Why?
Organoplatinum Compounds
2
2014
95
0.030
Why?
Erlotinib Hydrochloride
2
2008
88
0.030
Why?
Heart
1
2001
527
0.030
Why?
Gallbladder Neoplasms
1
2018
24
0.030
Why?
Neoplasm Invasiveness
2
2015
583
0.030
Why?
Programmed Cell Death 1 Receptor
1
2019
201
0.030
Why?
Kidney Pelvis
1
2018
47
0.030
Why?
Genetic Engineering
1
2018
102
0.030
Why?
Cell Cycle
1
2019
519
0.030
Why?
Patient Safety
1
2019
237
0.030
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2009
889
0.030
Why?
Isotretinoin
1
1997
22
0.030
Why?
Cholangiocarcinoma
1
2018
92
0.030
Why?
Antidotes
1
1997
24
0.030
Why?
Enhancer Elements, Genetic
1
2019
300
0.030
Why?
Injections
1
1997
131
0.030
Why?
Rats
1
2003
4079
0.030
Why?
Bile Duct Neoplasms
1
2018
106
0.030
Why?
HLA Antigens
1
2018
239
0.030
Why?
Injections, Subcutaneous
1
1997
142
0.030
Why?
Lymphocytes, Tumor-Infiltrating
1
2018
168
0.030
Why?
Repressor Proteins
1
2020
450
0.030
Why?
Acquired Immunodeficiency Syndrome
1
1997
68
0.030
Why?
Cytochrome P-450 CYP3A
2
2008
41
0.030
Why?
Tretinoin
1
1997
130
0.030
Why?
Signal Transduction
2
2019
3642
0.030
Why?
RNA, Messenger
3
2009
2076
0.030
Why?
Carcinoma, Transitional Cell
1
2018
158
0.030
Why?
Mitoxantrone
1
1996
65
0.030
Why?
RNA, Small Interfering
1
2018
573
0.030
Why?
Fever
1
1997
123
0.030
Why?
Estrone
1
2016
10
0.030
Why?
Bayes Theorem
1
2018
423
0.030
Why?
Follicle Stimulating Hormone
1
2016
132
0.030
Why?
Luteinizing Hormone
1
2016
147
0.030
Why?
Cell Survival
1
2018
1018
0.030
Why?
HIV-1
1
1997
179
0.030
Why?
Snake Venoms
1
2015
10
0.030
Why?
Phosphorylation
1
2018
1148
0.030
Why?
Postmenopause
2
2009
109
0.030
Why?
Protein Binding
1
2019
1564
0.030
Why?
Transcription Factors
1
2023
1724
0.030
Why?
MCF-7 Cells
1
2015
123
0.030
Why?
Registries
1
2021
1133
0.030
Why?
Drug Therapy, Combination
1
1997
766
0.030
Why?
Random Allocation
1
2015
312
0.030
Why?
Promoter Regions, Genetic
1
2018
979
0.030
Why?
Terminal Care
1
2016
147
0.030
Why?
Fluorocarbons
1
2015
64
0.030
Why?
Mice, SCID
1
2015
278
0.030
Why?
Vitamin D-Binding Protein
1
2014
7
0.030
Why?
Amyloid Precursor Protein Secretases
1
2015
101
0.030
Why?
Carcinoma, Non-Small-Cell Lung
2
2018
1177
0.030
Why?
Transcription, Genetic
1
2019
1136
0.030
Why?
Receptors, Interleukin-7
1
2014
30
0.030
Why?
Mesothelioma
1
2018
342
0.030
Why?
Immunotherapy, Adoptive
1
2018
336
0.030
Why?
Perception
2
2008
190
0.030
Why?
Multivariate Analysis
2
2009
1007
0.030
Why?
Cell Death
1
2015
258
0.030
Why?
Cyclohexenes
1
1994
5
0.030
Why?
Tumor Burden
1
2015
330
0.030
Why?
Benzofurans
1
1994
12
0.030
Why?
Australia
1
2014
126
0.030
Why?
Confidence Intervals
1
2014
221
0.030
Why?
Healthcare Disparities
1
2020
558
0.030
Why?
Receptors, Notch
1
2015
139
0.030
Why?
Biopsy
1
2018
1226
0.030
Why?
Clinical Decision-Making
1
2016
306
0.030
Why?
Hematologic Diseases
1
1994
77
0.020
Why?
Injections, Spinal
1
2013
49
0.020
Why?
Arylsulfotransferase
1
2013
4
0.020
Why?
Injections, Intravenous
1
2013
215
0.020
Why?
Sulfotransferases
1
2013
17
0.020
Why?
Carcinoma, Hepatocellular
1
2018
455
0.020
Why?
Severity of Illness Index
1
1999
2025
0.020
Why?
Cell Proliferation
1
2019
1801
0.020
Why?
National Cancer Institute (U.S.)
1
2013
77
0.020
Why?
Neoplastic Stem Cells
1
2015
191
0.020
Why?
Postoperative Period
1
2014
325
0.020
Why?
Trimetrexate
1
1992
4
0.020
Why?
Aminopterin
1
1992
5
0.020
Why?
Tetrahydrofolates
1
1992
15
0.020
Why?
Nigeria
1
2013
174
0.020
Why?
Hypertension
1
2019
791
0.020
Why?
Eligibility Determination
2
2003
42
0.020
Why?
Citrus paradisi
1
2012
5
0.020
Why?
Statistics as Topic
1
2013
229
0.020
Why?
Thiophenes
1
1992
46
0.020
Why?
Osteoporosis
1
2014
138
0.020
Why?
Clinical Trials, Phase II as Topic
1
2013
168
0.020
Why?
Gene Dosage
1
2013
216
0.020
Why?
Lymphopenia
1
2012
31
0.020
Why?
Skin Neoplasms
1
2018
638
0.020
Why?
Clinical Trials, Phase I as Topic
1
2013
154
0.020
Why?
Oligonucleotide Array Sequence Analysis
1
2014
700
0.020
Why?
Guidelines as Topic
1
2013
169
0.020
Why?
Vindesine
1
1992
5
0.020
Why?
Affinity Labels
1
1992
9
0.020
Why?
Pelvis
2
2003
106
0.020
Why?
Azides
1
1992
12
0.020
Why?
Chemistry, Physical
1
1992
29
0.020
Why?
Dihydropyridines
1
1992
7
0.020
Why?
Tritium
1
1992
114
0.020
Why?
Chemical Phenomena
1
1992
65
0.020
Why?
Hyperlipidemias
1
2012
93
0.020
Why?
Cricetulus
1
1992
125
0.020
Why?
Drug Combinations
2
2005
202
0.020
Why?
Vincristine
1
1992
102
0.020
Why?
Forecasting
1
1992
298
0.020
Why?
Tablets
1
2013
137
0.020
Why?
Iodine Radioisotopes
1
1992
145
0.020
Why?
Progesterone
1
1992
126
0.020
Why?
Drug Resistance
1
1992
234
0.020
Why?
Cricetinae
1
1992
535
0.020
Why?
Hyperglycemia
1
2012
187
0.020
Why?
Liver Neoplasms
1
2018
840
0.020
Why?
Cognition
1
2016
672
0.020
Why?
Carcinoma, Squamous Cell
1
2018
1107
0.020
Why?
Epithelium
1
1992
316
0.020
Why?
Drug Tolerance
1
1991
59
0.020
Why?
Bone Neoplasms
1
1993
316
0.020
Why?
Nasopharyngeal Diseases
1
1990
1
0.020
Why?
Otitis Media, Suppurative
1
1990
4
0.020
Why?
Otitis Media
1
1990
20
0.020
Why?
Sensitivity and Specificity
1
2014
1946
0.020
Why?
Radiotherapy Planning, Computer-Assisted
2
2002
215
0.020
Why?
Early Detection of Cancer
1
2015
563
0.020
Why?
Pseudomonas Infections
1
1990
95
0.020
Why?
Genetic Predisposition to Disease
1
2019
2588
0.020
Why?
Adenocarcinoma, Mucinous
1
2009
53
0.020
Why?
Climacteric
1
2008
4
0.020
Why?
Chemokine CXCL9
1
2008
8
0.020
Why?
Sick Role
1
2008
13
0.020
Why?
Chemokine CXCL10
1
2008
25
0.020
Why?
Placebos
1
2009
210
0.020
Why?
Polymorphism, Restriction Fragment Length
1
2008
145
0.020
Why?
Fluorodeoxyglucose F18
1
2009
146
0.020
Why?
Goserelin
1
2008
5
0.020
Why?
Neoplasms, Squamous Cell
1
2008
19
0.020
Why?
Mastectomy, Segmental
1
2009
119
0.020
Why?
Radiopharmaceuticals
1
2009
214
0.020
Why?
Thrombospondin 1
1
2008
22
0.020
Why?
E-Selectin
1
2008
31
0.020
Why?
Neuroblastoma
1
1992
410
0.020
Why?
Cytochrome P-450 Enzyme System
1
2008
77
0.020
Why?
Epithelial Cells
1
1992
710
0.020
Why?
Carcinoma, Papillary
1
2009
166
0.020
Why?
Spirituality
1
2008
112
0.020
Why?
Blotting, Western
1
2009
779
0.020
Why?
Exanthema
1
2008
43
0.020
Why?
Life Style
1
2008
193
0.020
Why?
ATP-Binding Cassette Transporters
1
2008
145
0.020
Why?
Positron-Emission Tomography
1
2009
354
0.020
Why?
Health Behavior
1
2008
203
0.020
Why?
Data Collection
1
2008
376
0.020
Why?
Cells, Cultured
1
1992
2859
0.020
Why?
Interferon-gamma
1
2008
478
0.020
Why?
Pregnancy
1
2014
3286
0.020
Why?
Carcinoma, Renal Cell
1
2011
384
0.020
Why?
Polymerase Chain Reaction
1
2008
895
0.020
Why?
Social Support
1
2008
246
0.010
Why?
Dimerization
1
2006
149
0.010
Why?
Genetic Variation
1
2013
1460
0.010
Why?
Microspheres
1
2006
99
0.010
Why?
Delayed-Action Preparations
1
2006
125
0.010
Why?
Radiodermatitis
1
2005
10
0.010
Why?
Lung
1
1992
1409
0.010
Why?
Cytochrome P-450 Enzyme Inhibitors
1
2004
9
0.010
Why?
Communication
1
2008
457
0.010
Why?
Cell Membrane
1
2007
681
0.010
Why?
Patient Education as Topic
1
2008
419
0.010
Why?
Cyclins
1
2004
80
0.010
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2004
76
0.010
Why?
Models, Biological
2
2002
1806
0.010
Why?
Mammaplasty
1
2005
129
0.010
Why?
Apoptosis
1
2009
1754
0.010
Why?
Chi-Square Distribution
1
2003
361
0.010
Why?
Wound Healing
1
2005
385
0.010
Why?
Metabolic Clearance Rate
1
2002
118
0.010
Why?
Therapeutic Equivalency
1
2002
16
0.010
Why?
Colorectal Neoplasms
1
2011
1120
0.010
Why?
Glucuronides
1
2002
34
0.010
Why?
Population
1
2002
36
0.010
Why?
Intestinal Absorption
1
2002
125
0.010
Why?
Liposomes
1
2001
105
0.010
Why?
Leukapheresis
1
2001
16
0.010
Why?
Cross-Over Studies
1
2002
394
0.010
Why?
Complement System Proteins
1
2001
87
0.010
Why?
Blood Coagulation
1
2001
90
0.010
Why?
Leukocyte Count
1
2001
215
0.010
Why?
Antigens, CD34
1
2001
162
0.010
Why?
Vascular Endothelial Growth Factors
1
2000
54
0.010
Why?
Matrix Metalloproteinases
1
2000
30
0.010
Why?
Endothelial Growth Factors
1
2000
55
0.010
Why?
Lymphokines
1
2000
74
0.010
Why?
Fibroblast Growth Factor 2
1
2000
57
0.010
Why?
Growth Substances
1
2000
79
0.010
Why?
Radiography
1
2002
763
0.010
Why?
Lactones
1
2000
28
0.010
Why?
Macrolides
1
2000
34
0.010
Why?
Stem Cells
1
2001
399
0.010
Why?
Alleles
1
2002
1163
0.010
Why?
Cost-Benefit Analysis
1
2001
521
0.010
Why?
Lymphoma, AIDS-Related
1
1997
7
0.010
Why?
Sarcoma, Kaposi
1
1997
17
0.010
Why?
South Africa
1
1997
64
0.010
Why?
Tumor Necrosis Factor-alpha
1
2000
712
0.010
Why?
Linear Models
1
1996
428
0.010
Why?
Analysis of Variance
1
1996
890
0.010
Why?
Tomography, X-Ray Computed
1
1990
2680
0.000
Why?
Fleming's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (645)
Explore
_
Co-Authors (75)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_